TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01864161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gluconate iron
Description: FERLIXIT fl 15mg/kg divided into weekly administrations of 125mg up to a maximum of 1000mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal iron
Description: Sideral forte 30 mg/die
Study: NCT04102722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MUST device
Description: Imaging with MUST device
Study: NCT01423474

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-guided radiotherapy
Description: 40 Gy / 5 fractions / 11 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-guided radiotherapy
Description: 40 Gy / 5 fractions / 29 days
Study: NCT02132273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Story
Description: Educational story with pictures illustrating overnight polysomnography procedure accompanied by simple narrative.
Study: NCT02413411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DA/MI Intervention
Description: Patients randomized to the DA/MI intervention arm will be shown a decision aid video entitled, Treatment Choices for Knee Osteoarthritis. Following the viewing of the decision aid video, the participant will be engaged in a motivational interview by the research study interventionist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: an educational program (an NIH-developed booklet)
Study: NCT00631527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex
Description: Once a day by mouth for 2 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Radiation treatment once daily over a period of 8 weeks.
Study: NCT01198054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Initial dose of oral lenalidomide is 10 mg/day for 28 days every 28 days, during 6 months.~In case of response on day 169, patient will follow a treatment extension phase. The dose of lenalidomide should be the same as the last dose for initial phase, until 24 months or progression disease
Study: NCT00499902

Intervention type: DRUG
Group type: OTHER
Intervention: alfimeprase
Description: Alfimeprase will be given as a single bolus of 1mg/2mL, or a split bolus of 5mg/2mL or 10mg/2mL in a three-tier dose escalation format. The 5mg and 10mg doses will be administered as split doses with 1/2 of the total dose given initially and 1/2 of the total dose given 30 minutes after the initial dose.
Study: NCT01760811

Intervention type: DRUG
Group type: OTHER
Intervention: Erbitux,merck serono
Description: cetuximab loading dosage 400mg/m2 followed by weekly 250mg/m2 2 weeks
Study: NCT02017561

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Counseling
Description: Written and individualized information during the interview in all clinic visits, emphasizing the importance of a healthy lifestyle, engaging on regular moderate-intensity physical activity and eating an healthy diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: Written and individualized information during the interview in all clinic visits, emphasizing the importance of a healthy lifestyle, engaging on regular moderate-intensity physical activity and eating an healthy diet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin treatment titrated to a maximum dose of 1000mg twice a day. Metformin treatment will start with 500mg at breakfast during the first week and, if well tolerated, increased to 500mg twice a day (breakfast and dinner) in the second week, 1000mg at breakfast and 500mg at dinner in the third week and finally for the target dose of 1000mg twice a day.
Study: NCT02965690

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Zimmer Biomet NexGen CR
Description: Total Knee Replacement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medacta International GMK Sphere
Description: Total Knee Replacement
Study: NCT02564328

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous stem cell transplantation
Description: Intravenous injection of autologous bone marrow mesenchymal stem cell transplantation
Study: NCT01914406

Intervention type: OTHER
Group type: OTHER
Intervention: high intense interval training
Description: Each AIT session consisted a 10 minute warm-up period followed by 16 minutes of interval training consisting of intervals of 4-3-2 and 1 minutes duration at 85-95% of their peak capacity separated by 2-4 min active rest.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous moderate training
Description: Continued exercise 45 min.
Study: NCT01894165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1101
Description: Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
Study: NCT01163708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prophecy Technique
Description: Navigation computerised system is used intraoperatively to correct implant the Advance knee implant. Prophecy is a pre-alignment technique where a pre-op MRI or CT scan is used to manufacture personalised cutting blocks to assist the surgeon in correct implanting the Advance knee implant intraoperatively

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Navigation System
Study: NCT01236937

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bellows-based breath hold device
Description: Bellows-Based breath hold monitoring system:~The bellows-based breath hold system (IBC, Mayo Clinic Medical Devices, USA) contains of 2 elements; one belt which is strapped around the thorax of the patient and a voltage controlled light unit with 8 lights. Belt stretch from respiratory motion is converted into voltage readings and displayed on the light unit giving biofeedback as different lights are activated depending on the dept of the respiration. Patients are instructed to keep respiration constant at a certain dept during the second the guide needle is inserted by controlling their breath with the help of the light unit. The patient is given a brief introduction to the system as to how the lights get turned on and off due to respiration motion before the biopsy is preformed.

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Bellows-based breath hold device
Description: Bellows-Based breath hold monitoring system:~The bellows-based breath hold system (IBC, Mayo Clinic Medical Devices, USA) contains of 2 elements; one belt which is strapped around the thorax of the patient and a voltage controlled light unit with 8 lights. Belt stretch from respiratory motion is converted into voltage readings and displayed on the light unit giving biofeedback as different lights are activated depending on the dept of the respiration. Patients are instructed to keep respiration constant at a certain dept during the second the guide needle is inserted by controlling their breath with the help of the light unit. The patient is given a brief introduction to the system as to how the lights get turned on and off due to respiration motion before the biopsy is preformed.
Study: NCT02115711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community health worker
Description: The intervention is a multi-component one that is tailored to the individual and will target lifestyle changes, health seeking behavior and medication compliance. The CHW, after identifying the cardiovascular risk factors, will give advice about lifestyle interventions and will encourage hypertensives and diabetics to seek a physician. The first phase of the intervention will target hypertension, while the second phase which will be introduced 6 months after the first visit will target diabetes and smoking. The CHW will continue visiting the home of the participants every 2 months to reinforce the previous recommendations, seek to address reasons for non-adherence, address knowledge deficits and encourage physician visits.
Study: NCT04157608

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habitual Prosthesis
Description: Habitual baseline prosthesis prescribed by participant's clinician.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy-Harvesting Mesofluidic Impulse Prosthesis
Description: e-MIP is an experimental lower limb ankle-foot prosthesis.
Study: NCT03311659

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix
Description: One dose administered intramuscularly in the deltoid muscle of the non-dominant arm in dTap group.
Study: NCT03504696

Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional
Study: NCT01998698

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification surgery
Description: Phacoemulsification surgery with intraocular lens implantation and monovision correction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification surgery
Description: Phacoemulsification surgery with multifocal intraocular lens implantation
Study: NCT03747432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Procedural sedation during TAVR procedure using propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Procedural sedation during TAVR procedure using dexmedetomidine
Study: NCT04287712

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma lipids
Description: Plasma lipids were detected by an Ultimate 3000 ultra-high-performance liquid chromatography (UHPLC) system coupled with Q-Exactive MS (Thermo Scientific) . Then a detection model was built based on plasma lipids using machine learning algorithm.
Study: NCT02229136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miracle Mouthwash Plus Hydrocortisone
Description: Miracle Mouthwash Plus Hydrocortisone (16 oz recipe/480 ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone oral solution 15 mg/5 ml
Study: NCT02051777

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral Nutritional Supplement 1
Description: Containing macro and micronutrients
Study: NCT02703688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Homes
Description: The Healthy Homes Behavioral Intervention (HHBI) will be delivered during 8 sessions over 10 weeks using home visitations. The first 6 sessions occur weekly and provide education about healthy dietary intake including caloric recommendations for preschool aged children, healthy sleep goals, active play and screen time limits, and family routines and organization. Each session will include a parent-child interaction component to teach child behavior management skills related to intervention goals. Two final sessions occur every other week to provide problem solving and planning for maintenance of treatment effects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: A pediatrician with experience delivering weight management treatment to children will deliver a single session, 1-hour treatment to families. Content to be delivered during the session will include lifestyle recommendations currently recommended by the AAP.
Study: NCT00513955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study: NCT03829956

Intervention type: DEVICE
Group type: OTHER
Intervention: Intraoral tongue stimulator (Snoozeal)
Description: Electrical stimulation of the tongue muscle to improve muscle tone to treat primary snoring and mild obstructive sleep apnea.
Study: NCT00810940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbelaDrug200
Description: IV 200 ml 28%drug in D5W every six hours, 10 min. duration, until ICP \< 20 mmHg, then IV 100 ml same schedule for 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mannitol
Description: mannitol plus standard treatment
Study: NCT02051777

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral Nutritional Supplement 2
Description: Containing macro and micronutrients

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary Advice

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary Advice
Study: NCT03792152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, then start with rivaroxaba 20mg qd (15mg If creatinine clearance is between 30-49 ml/min).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: After the diagnosis of left atrial appendage thrombus by transesophageal echocardiography, subcutaneous injection of low molecular weight heparin (4000iu q12h) and oral warfarin treatment were started, and low molecular weight heparin was stopped after INR reached 2.
Study: NCT00457223

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation using fibrin glue
Description: After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®) in 16 eyes of 16 patients of FG group and continuous suture with nylon 10-0 in 16 eyes of 16 patients of SU group.
Study: NCT02051777

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary Advice
Study: NCT00457223

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic membrane transplantation using fibrin glue
Description: After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®) in 16 eyes of 16 patients of FG group and continuous suture with nylon 10-0 in 16 eyes of 16 patients of SU group.
Study: NCT02363322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A/Current Standard of Care Alone
Description: Optimized standard of care for Ebola virus infection
Study: NCT00552006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. In cooperation with the therapist the clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.~NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Academic Counseling
Description: Missing time in educational life is one major issue for formerly abducted people. The Academic Counseling (AC) intervention is an active Control condition and improves English skills and works at the same time on concentration, learning and memory abilities. The clients will gain some of the abilities and skills they might have lost or developed weaknesses in due to their abduction.~AC will be applied in eight sessions (90-120min/session) in a standardized, manualized manner.
Study: NCT03130452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole 30mg
Description: lansoprazole 30 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30mg
Description: lansoprazole 30 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30mg
Description: lansoprazole 30 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 1.0g Tab
Description: Amoxicillin 1.0g tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 1.0g Tab
Description: Amoxicillin 1.0g tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500mg
Description: Clarithromycin 500mg tablet
Study: NCT00106626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin
Description: Dose escalation study starting with vorinostat (Suberoylanilide Hydroxamic Acid \[SAHA\]) capsules 200 mg b.i.d. in combination with Pemetrexed and Cisplatin (see table for Reporting Groups).
Study: NCT00732199

Intervention type: OTHER
Group type: OTHER
Intervention: 1) hyperventilation via noninvasive positive pressure ventilation 2) multiple trials of episodic hypoxia
Description: 1) noninvasive hyperventilation to determine apneic threshold; 2) episodic hypoxia to determine ventilatory long term facilitation
Study: NCT03130452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: Clarithromycin 500mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: Clarithromycin 500mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 500 mg
Description: Metronidazole 500 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg
Description: Metronidazole 500 mg tablet
Study: NCT03100214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive an early rehabilitation program, which will begin within the first 48 hours after admission. The patient will perform physical training (aerobic and anaerobic) 5 times a week during the hospitalization period, with sessions about an hour. The professional who supervises the training will be blinded to the results of the measurements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients randomized to the control group will continue to receive the physiotherapeutic follow-up performed by the physiotherapist of the Program for Adults with CF during the hospitalization period. Supervision includes respiratory physiotherapy involving inhalation therapy and techniques for removal of secretions
Study: NCT00732199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1) hyperventilation via noninvasive positive pressure ventilation 2) multiple trials of episodic hypoxia
Description: 1) noninvasive hyperventilation to determine apneic threshold; 2) episodic hypoxia to determine ventilatory long term facilitation
Study: NCT00517673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK945237

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Placebo
Study: NCT04255329

Intervention type: OTHER
Group type: OTHER
Intervention: Montessori reading roundtable
Description: Such book is written in a way to adaptate to people with cognitif and sensory impairments. Indeed, text is written in large characters and structured to not involve episodic memory. Each person read one page aloud in his turn. After the reading phase, the participants discuss the questions about their opinions and distant memories.
Study: NCT03234231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-month supervised tooth brushing programme
Description: One or a few dental hygienists, who are trained to teach how to brush and provide scaling, will supervise the students to brush daily in school for three months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: oral health education talk
Description: It is conducted by a dentist, while written materials will be delivered to the students and their carers.
Study: NCT03323671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preemptive mefenamic acid
Description: preemptive analgesia before menstrual pain
Study: NCT04255329

Intervention type: OTHER
Group type: OTHER
Intervention: Usual reading
Description: The readen text is a normal, currently used in a everyday life support such as a journal article.
Study: NCT03323671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mefenamic acid
Description: mefenamic acid given only during menstruation
Study: NCT05301738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric Exercises
Description: The plyometric exercise group received a 12-week plyometric training program. Each session lasted 45 minutes and was repeated two times a week. The training was conducted in conformity with the National Strength and Conditioning Association guidelines and American Academy of Pediatrics safety standards. The plyometric exercise program consisted of ten unilateral and bilateral lower limb plyometrics in the form of hopping/bounding/jumping activities. The Iplyometric workout was proceeded by a 5-minute warm-up and ended up with a 5-minute cool-down

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy
Description: The control group received their usual physical rehabilitation program for 45 minutes, twice/week for 12 consecutive weeks. The program comprised advanced balance training, and gait training exercises, postural and flexibility exercises, strength training exercises.
Study: NCT01238978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study: NCT02059954

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterectomy
Study: NCT00330668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rh IGF-1 (mecasermin)
Description: Patients from untreated arm for prior study MS301 (NCT00125164) were randomized to a dose of either 80 or 120 mcg/kg twice daily. For patients receiving active treatment in previous study MS 301 (NCT00125164), they started on a dose of 80 or 120 mcg/kg twice daily based on the dose reached at end of the previous study. Following a protocol amendment in May 2009, all patients were switched to once daily doses of 160 µg/kg, escalated to a targeted maximum dose of 240 µg/kg.
Study: NCT01096810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBL 12
Description: TBL 12 will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression.
Study: NCT01819454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pH monitoring (Restech)
Description: see in detail description of the study part of the protocol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pH monitoring (Restech)
Description: see in detail description of the study part of the protocol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pH monitoring (Restech)
Description: see in detail description of the study part of the protocol